Abdullah A Alqarni, Abdulelah M Aldhahir, Heba M Bintalib, Jaber S Alqahtani, Rayan A Siraj, Mansour Majrshi, Abdulkareem A AlGarni, Abdallah Y Naser, Sara A Alghamdi, Hassan Alwafi
BACKGROUND: Pulmonary hypertension due to chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) is classified as group 3 pulmonary hypertension. Inhaled treprostinil, a prostaglandin I2 analogue also known as prostacyclin, has recently been approved as a first drug for patients with pulmonary hypertension secondary to ILD. However, due to a lack of evidence, no therapies are currently approved for those with COPD-associated pulmonary hypertension. Thus, this systematic review aims to summarise the current evidence to assess the impact of inhaled prostaglandin I2 analogue use on the pulmonary hemodynamics, exercise function, lung function, and gas exchange in patients with pulmonary hypertension due to COPD...
2023: Frontiers in Medicine